Ana-Maria Vranceanu, Ph.D.
This page shows the publications co-authored by Ana-Maria Vranceanu and Scott Plotkin.
Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial. JMIR Res Protoc. 2018 Oct 23; 7(10):e11008.
Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT. Neurology. 2016 Aug 23; 87(8):806-14.
Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. J Neurooncol. 2015 Apr; 122(2):219-28.
Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol. 2013 Sep; 114(3):257-62.
Improvement in resiliency factors among adolescents with neurofibromatosis who participate in a virtual mind-body group program. J Neurooncol. 2020 Apr; 147(2):451-457.
Virtual mind-body treatment for geographically diverse youth with neurofibromatosis: A pilot randomized controlled trial. Gen Hosp Psychiatry. 2020 Jan - Feb; 62:72-78.
Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live-video randomized control trial. J Neurooncol. 2019 Dec; 145(3):561-569.
First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial. J Neurooncol. 2019 Jul; 143(3):505-513.
Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT. J Neurooncol. 2018 Jan; 136(2):335-342.
First report of factors associated with satisfaction in patients with neurofibromatosis. . 2017 03; 173(3):671-677.
First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis. J Neurooncol. 2017 01; 131(2):413-419.
Health-related Quality of Life of Individuals With Neurofibromatosis Type 2: Results From the NF2 Natural History Study. Otol Neurotol. 2016 06; 37(5):574-9.
Examining perceived cancer risk among patients with neurofibromatosis type 1. J Neurooncol. 2015 Mar; 122(1):127-33.
The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study. J Neurooncol. 2014 Oct; 120(1):103-9.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.